Novel Abeta Vaccine Reports First Human Data

Aggregates of beta-amyloid protein (Abeta) and other malformed proteins accumulate in both “normal” brain aging and neurodegenerative disease, leading to neuronal loss. Their removal by immunotherapy is a central plank of the SENS platform, and the most clinically advanced. Gantenerumab, a new fully human anti-Abeta monoclonal antibody, has just completed a Phase I trial.

Read more...

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2023 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can

SENS Research Foundation Audience Survey

And follow the link at the end to WIN!: